 | • レポートコード：TPM-NV163 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、200ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、乾癬治療の世界市場について調べ、乾癬治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（TNF阻害剤、インターロイキン阻害剤、ビタミンD類縁体、コルチコステロイドなど）分析、投与経路別（経口、非経口、および局所）分析、流通チャンネル別（病院薬局、小売薬局、およびその他）分析、関連企業情報などをまとめました。 ・乾癬治療の市場概要 ・乾癬治療の市場動向 ・乾癬治療の世界市場規模・予測 ・乾癬治療市場：薬物クラス別（TNF阻害剤、インターロイキン阻害剤、ビタミンD類縁体、コルチコステロイドなど） ・乾癬治療市場：投与経路別（経口、非経口、および局所） ・乾癬治療市場：投与経路別（経口、非経口、および局所） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Even as healthcare, as a whole, is transitioning slowly towards value-based care for better patient outcomes and improved quality of life, increase in the prevalence of psoriasis, globally, is spurring investments toward its treatment and management methods. This has resulted in manufacturers in the psoriasis treatment market focussing on research & development for better disease management, which has led to the innovation of newer drugs that are more efficient. For instance, in April 2019, Samsung Bioepis’ – Eticovo, the second biosimilar of Etanercept, was approved by the FDA for the treatment of psoriasis in moderate to severe cases.
With biologics gradually losing their exclusivity and becoming increasingly accessible, they are expected to positively contribute to the growth of the global psoriasis treatment market. According to this study by Transparency Market Research, in 2018, the market was valued at ~US$ 13.8 Bn, and is set to hit the ~US$ 35.7 Mn by the end of the forecast period.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Psoriasis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by Region/Key Country
5.2. Psoriasis Treatment Market Pipeline Analysis
5.3. Key Mergers & Acquisitions
6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
6.3.1. TNF Inhibitors
6.3.2. Interleukin Inhibitors
6.3.3. Vitamin D Analogs
6.3.4. Corticosteroids
6.3.5. Others
6.4. Market Attractiveness, by Drug Class
7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
7.3.1. Oral
7.3.2. Parenteral
7.3.3. Topical
7.4. Market Attractiveness By Route of Administration
8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel
9. Global Psoriasis Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Psoriasis Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Psoriasis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
10.2.1. TNF Inhibitors
10.2.2. Interleukin Inhibitors
10.2.3. Vitamin D Analogs
10.2.4. Corticosteroids
10.2.5. Others
10.3. North America Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
10.3.1. Oral
10.3.2. Parenteral
10.3.3. Topical
10.4. North America Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. North America Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Psoriasis Treatment Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Psoriasis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Others
11.2. Europe Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
11.2.1. TNF Inhibitors
11.2.2. Interleukin Inhibitors
11.2.3. Vitamin D Analogs
11.2.4. Corticosteroids
11.2.5. Others
11.3. Europe Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
11.3.1. Oral
11.3.2. Parenteral
11.3.3. Topical
11.4. Europe Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Europe Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Psoriasis Treatment Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
12.2.1. TNF Inhibitors
12.2.2. Interleukin Inhibitors
12.2.3. Vitamin D Analogs
12.2.4. Corticosteroids
12.2.5. Others
12.3. Asia Pacific Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
12.3.1. Oral
12.3.2. Parenteral
12.3.3. Topical
12.4. Asia Pacific Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Asia Pacific Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Psoriasis Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Psoriasis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
13.2.1. TNF Inhibitors
13.2.2. Interleukin Inhibitors
13.2.3. Vitamin D Analogs
13.2.4. Corticosteroids
13.2.5. Others
13.3. Latin America Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
13.3.1. Oral
13.3.2. Parenteral
13.3.3. Topical
13.4. Latin America Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Latin America Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Psoriasis Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Drug Class, 2017–2027
14.2.1. TNF Inhibitors
14.2.2. Interleukin Inhibitors
14.2.3. Vitamin D Analogs
14.2.4. Corticosteroids
14.2.5. Others
14.3. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Route of Administration, 2017–2027
14.3.1. Oral
14.3.2. Parenteral
14.3.3. Topical
14.4. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Others
14.5. Middle East & Africa Psoriasis Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Share Analysis, by Company, 2018
15.2. Company Profiles
15.2.1. Amgen, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. Eli Lilly and Company
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Novartis AG
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. Merck & Co., Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Johnson & Johnson
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Pfizer, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. AstraZeneca plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. AbbVie, Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. LEO Pharma A/S
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
15.2.10. Biogen, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Strategic Overview
15.2.10.5. SWOT Analysis